Company intelligence / Profile preview

AVAR BioTherapeutics

Worcester, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

AVAR BioTherapeutics is a biotechnology company focused on developing next-generation adeno-associated virus (AAV) gene therapies for rare and prevalent diseases. Co-founded by world-renowned AAV experts Dr. Guangping Gao and Dr. Jun Xie from UMass Chan Medical School, the company utilizes a proprietary capsid engineering platform to design viral vectors with enhanced tissue tropism and reduced off-target effects. Their primary focus is on addressing unmet needs in central nervous system (CNS) disorders and metabolic conditions. AVAR BioTherapeutics aims to overcome the limitations of current gene delivery systems to provide safer and more effective therapeutic options for patients worldwide.

Therapeutic areas: Rare DiseasesNeurologyMetabolic Disorders
Modalities: Gene therapy
Industry: Biotech

Beyond the preview

Go deeper on AVAR BioTherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVAR BioTherapeutics.

Explore the full profile